Diagnostic value of a panel of tumor-associated autoantibodies for breast cancer
10.3760/cma.j.cn114452-20240822-00468
- VernacularTitle:肿瘤相关自身抗体在乳腺癌诊断中的意义
- Author:
Fengming YANG
1
;
Linping YAN
1
;
Xuelian MAO
1
;
Dongping MO
1
;
Feng YAN
1
Author Information
1. 江苏省肿瘤医院 南京医科大学附属肿瘤医院 江苏省肿瘤防治研究所检验科，南京210009
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Tumor associated antigen;
Tumour-associated autoantibody;
Enzyme-linked immunosorbent assay;
Diagnosis
- From:
Chinese Journal of Laboratory Medicine
2025;48(6):722-729
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the diagnostic performance of a panel of autoantibodies against multiple tumor-associated antigens (BRCA2, P53, ANXA11, PARP1, TRIM21, ATAD2, NY-ESO-1 and CAGE) in the detection of breast cancer.Methods:This was a retrospective case-control study. A total of 545 patients diagnosed with breast cancer (BC) by pathological examination, and eligible for enrolment at Jiangsu Cancer Hospital from January 2022 to December 2023 were selected as the patient group. In the same period, 200 patients with benign breast disease (BD) and 200 healthy individuals (HC) were included. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of tumor-associated autoantibodies in each group. The tumor markers including carcinoembryonic antigen (CEA), glycoconjugate antigen 125 (CA125) and glycoconjugate antigen 153 (CA153) were detected using electrochemiluminescence. Univariate and multivariate logistic regression analyses were used to screen the factors associated with breast cancer. The receiver operating characteristic (ROC) curve was applied to evaluate diagnostic value.Results:The levels of seven autoantibodies against BRCA2, P53, ANXA11, PARP1, ATAD2, NY-ESO-1 and CAGE were significantly higher in the BC group compared to HC group (all P<0.05). Additionally, the levels of six autoantibodies against BRCA2, P53, PARP1, ATAD2, NY-ESO-1 and CAGE were significantly higher in the BC group than those in BD group (all P<0.05). The levels of PARP1 and ATAD2 in the BD group were higher than those in HC group ( P<0.05). Logistic multivariate analysis revealed that BRCA2 ( OR=1.099, 95% CI 0.824-1.107), P53 ( OR=1.534, 95% CI 0.813-2.898), NY-ESO-1( OR=1.159, 95% CI 0.789-1.712) and CA153 ( OR=1.029, 95% CI 0.778-1.495) were potential indicators for breast cancer (all P<0.05). The ROC curves indicated that the AUCs for breast cancer using BRCA2, P53, NY-ESO-1, and CA153 were 0.602 (95% CI 0.549-0.635), 0.688 (95% CI 0.642-0.734), 0.729 (95% CI 0.677-0.781), 0.714 (95% CI 0.663-0.764), respectively. The sensitivities were 0.405, 0.588, 0.683 and 0.653, while the specificities were 0.770, 0.825, 0.851 and 0.790, respectively. The AUC of the combined detection including BRCA2, P53, NY-ESO-1, and CA153 for breast cancer was 0.857 (95% CI 0.832-0.883), with a sensitivity of 0.719 and a specificity of 0.835. Conclusions:The levels of tumor-associated autoantibodies to BRCA2, P53 and NY-ESO-1 were significantly elevated in breast cancer patients, and the combination of the three autoantibodies and CA153 has high diagnostic value for breast cancer.
